Galderma Group AG’s Nemluvio Drives Strong Buy Rating Amid Impressive Prescription Growth

Galderma Group AG (GALD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Benjamin Jackson CFA from Jefferies maintained a Buy rating on the stock and has a CHF112.00 price target.

Benjamin Jackson CFA has given his Buy rating due to a combination of factors including the impressive performance of Galderma Group AG’s Nemluvio product. The US prescription volumes for Nemluvio have shown a significant 15% week-over-week growth, surpassing even the most optimistic projections. This robust volume growth indicates strong market demand and positions the company favorably against its competitors.
Moreover, the average number of prescriptions that account for two pens is currently at 43% for the quarter-to-date, which is higher than the anticipated 35% for the second quarter. This performance suggests that Nemluvio is outperforming expectations, providing a cushion against any potential future market fluctuations. However, the uncertainty around net pricing evolution remains a factor to watch, with more clarity expected from the first-half earnings report. Overall, these positive indicators support the Buy rating as Galderma Group AG demonstrates strong potential for growth.